Hybrid versus vaccine immunity of mRNA-1273 among people living with HIV in East and Southern Africa: a prospective cohort analysis from the multicentre CoVPN 3008 (Ubuntu) studyResearch in context
Summary: Background: With limited access to mRNA COVID-19 vaccines in lower income countries, and people living with HIV (PLWH) largely excluded from clinical trials, Part A of the multicentre CoVPN 3008 (Ubuntu) study aimed to assess the safety of mRNA-1273, the relative effectiveness of hybrid ve...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-02-01
|
| Series: | EClinicalMedicine |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2589537024006333 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832591757380943872 |
|---|---|
| author | Nigel Garrett Asa Tapley Aaron Hudson Sufia Dadabhai Bo Zhang Nyaradzo M. Mgodi Jessica Andriesen Azwidihwi Takalani Leigh H. Fisher Jia Jin Kee Craig A. Magaret Manuel Villaran John Hural Erica Andersen-Nissen Guido Ferarri Maurine D. Miner Bert Le Roux Eduan Wilkinson Richard Lessells Tulio de Oliveira Jackline Odhiambo Parth Shah Laura Polakowski Margaret Yacovone Taraz Samandari Zvavahera Chirenje Peter James Elyanu Joseph Makhema Ethel Kamuti Harriet Nuwagaba-Biribonwoha Sharlaa Badal-Faesen William Brumskine Soritha Coetzer Rodney Dawson Sinead Delany-Moretlwe Andreas Henri Diacon Samantha Fry Katherine Margaret Gill Zaheer Ahmed Ebrahim Hoosain Mina C. Hosseinipour Mubiana Inambao Craig Innes Steve Innes Dishiki Kalonji Margaret Kasaro Priya Kassim Noel Kayange William Kilembe Fatima Laher Moelo Malahleha Vongane Louisa Maluleke Grace Mboya Kirsten McHarry Essack Mitha Kathryn Mngadi Pamela Mda Tumelo Moloantoa Cissy Kityo Mutuluuza Nivashnee Naicker Vimla Naicker Anusha Nana Annet Nanvubya Maphoshane Nchabeleng Walter Otieno Elsje Louise Potgieter Disebo Potloane Zelda Punt Jamil Said Yashna Singh Mohammed Siddique Tayob Yacoob Vahed Deo Ogema Wabwire M. Juliana McElrath James G. Kublin Linda-Gail Bekker Peter B. Gilbert Lawrence Corey Glenda E. Gray Yunda Huang Philip Kotze Sharlaa Badal-Faesen Kagisho Baepanye Veronique Bailey Katekani Baloyi-Oseh Mumtaz Booley Johannes Louis Botha Yolande Brown Valerie Brown Lisa Bunts Soritha Coetzer Myron Cohen Shirley Collie Rodney Dawson Pallabi Deb Hana El Sahly Jill El-Khorazaty Andries Engelbrecht Marianne Gildea Dhevium Govender Jen Hanke Jayla Harris Simone Hendricks Nick Hopkinson Haley Howell Nzeera Ketter Kentse Khuto Faatima Laher Omar Leolin Katsidzira Kim Linton James Ludwig Bongile Mabilane Matshidiso Malefo Ndiitwani Mamushiana Daciana Margineantu Jeanine May Fatima Mayat Cindy Molitor Yeshnee Naidoo Michelle Nebergall Alan Nguyen Sarah Nikles Bianca Noronha Melissa Peda Tamara Phiri Shanthie Pillay Sureshnee Pillay Lori Proulx-Burns Laurie Rinn Lisa Sanders Carrie Sopher Smitha Sripathy Michael Stirewalt Houriiyah Tegally Sara Thiebaud Alicia Toledano Stephanie Van Wyk Shamaya Whitby Stephany Wilcox Eduan Wilkinson Haven Wilvich Charles Wiysonge Nelisiwe Xaba Ntokozo Xulu |
| author_facet | Nigel Garrett Asa Tapley Aaron Hudson Sufia Dadabhai Bo Zhang Nyaradzo M. Mgodi Jessica Andriesen Azwidihwi Takalani Leigh H. Fisher Jia Jin Kee Craig A. Magaret Manuel Villaran John Hural Erica Andersen-Nissen Guido Ferarri Maurine D. Miner Bert Le Roux Eduan Wilkinson Richard Lessells Tulio de Oliveira Jackline Odhiambo Parth Shah Laura Polakowski Margaret Yacovone Taraz Samandari Zvavahera Chirenje Peter James Elyanu Joseph Makhema Ethel Kamuti Harriet Nuwagaba-Biribonwoha Sharlaa Badal-Faesen William Brumskine Soritha Coetzer Rodney Dawson Sinead Delany-Moretlwe Andreas Henri Diacon Samantha Fry Katherine Margaret Gill Zaheer Ahmed Ebrahim Hoosain Mina C. Hosseinipour Mubiana Inambao Craig Innes Steve Innes Dishiki Kalonji Margaret Kasaro Priya Kassim Noel Kayange William Kilembe Fatima Laher Moelo Malahleha Vongane Louisa Maluleke Grace Mboya Kirsten McHarry Essack Mitha Kathryn Mngadi Pamela Mda Tumelo Moloantoa Cissy Kityo Mutuluuza Nivashnee Naicker Vimla Naicker Anusha Nana Annet Nanvubya Maphoshane Nchabeleng Walter Otieno Elsje Louise Potgieter Disebo Potloane Zelda Punt Jamil Said Yashna Singh Mohammed Siddique Tayob Yacoob Vahed Deo Ogema Wabwire M. Juliana McElrath James G. Kublin Linda-Gail Bekker Peter B. Gilbert Lawrence Corey Glenda E. Gray Yunda Huang Philip Kotze Sharlaa Badal-Faesen Kagisho Baepanye Veronique Bailey Katekani Baloyi-Oseh Mumtaz Booley Johannes Louis Botha Yolande Brown Valerie Brown Lisa Bunts Soritha Coetzer Myron Cohen Shirley Collie Rodney Dawson Pallabi Deb Hana El Sahly Jill El-Khorazaty Andries Engelbrecht Marianne Gildea Dhevium Govender Jen Hanke Jayla Harris Simone Hendricks Nick Hopkinson Haley Howell Nzeera Ketter Kentse Khuto Faatima Laher Omar Leolin Katsidzira Kim Linton James Ludwig Bongile Mabilane Matshidiso Malefo Ndiitwani Mamushiana Daciana Margineantu Jeanine May Fatima Mayat Cindy Molitor Yeshnee Naidoo Michelle Nebergall Alan Nguyen Sarah Nikles Bianca Noronha Melissa Peda Tamara Phiri Shanthie Pillay Sureshnee Pillay Lori Proulx-Burns Laurie Rinn Lisa Sanders Carrie Sopher Smitha Sripathy Michael Stirewalt Houriiyah Tegally Sara Thiebaud Alicia Toledano Stephanie Van Wyk Shamaya Whitby Stephany Wilcox Eduan Wilkinson Haven Wilvich Charles Wiysonge Nelisiwe Xaba Ntokozo Xulu |
| author_sort | Nigel Garrett |
| collection | DOAJ |
| description | Summary: Background: With limited access to mRNA COVID-19 vaccines in lower income countries, and people living with HIV (PLWH) largely excluded from clinical trials, Part A of the multicentre CoVPN 3008 (Ubuntu) study aimed to assess the safety of mRNA-1273, the relative effectiveness of hybrid versus vaccine immunity, and SARS-CoV-2 viral persistence among PLWH in East and Southern Africa during the omicron outbreak. Methods: Previously unvaccinated adults with HIV and/or other comorbidities associated with severe COVID-19 received either one (hybrid immunity) or two (vaccine immunity) 100-mcg doses of ancestral strain mRNA-1273 in the first month, depending on baseline evidence of prior SARS-CoV-2 infection. In a prospective cohort study design, we used covariate-adjusted Cox regression and counterfactual cumulative incidence methods to determine the hazard ratio and relative risk of COVID-19 and severe COVID-19 with hybrid versus vaccine immunity within six months. The ongoing Ubuntu study is registered on ClinicalTrials.gov (NCT05168813) and this work was conducted from December 2021 to March 2023. Findings: Between December 2021 and September 2022, 14,237 participants enrolled, and 14,002 (83% PLWH, 69% SARS-CoV-2 seropositive) were included in the analyses. Vaccinations were safe and well tolerated. Common adverse events were pain or tenderness at the injection site (26.7%), headache (20.4%), and malaise (20.3%). Severe adverse events were rare (0.8% of participants after the first and 1.1% after the second vaccination), and none were life-threatening or fatal. Among PLWH, the median CD4 count was 635 cells/μl and 18.5% had HIV viraemia. The six-month cumulative incidences in the hybrid immunity and vaccine immunity groups were 2.02% (95% confidence interval [CI] 1.61–2.44) and 3.40% (95% CI 2.30–4.49) for COVID-19, and 0.048% (95% CI 0.00–0.10) and 0.32% (95% CI 0.59–0.63) for severe COVID-19. Among all PLWH the hybrid immunity group had a 42% lower hazard rate of COVID-19 (hazard ratio [HR] 0.58; 95% CI 0.44–0.77; p < 0.001) and a 73% lower hazard rate of severe COVID-19 (HR 0.27; 95% CI 0.07–1.04; p = 0.056) than the vaccine immunity group, but this effect was not seen among PLWH with CD4 counts <350 cells/μl or HIV viraemia. Twenty PLWH had persistent SARS-CoV-2 virus at least 50 days. Interpretation: Hybrid immunity was associated with superior protection from COVID-19 compared to vaccine immunity with the ancestral mRNA-1273 vaccine. Persistent infections among immunocompromised PLWH may provide reservoirs for emerging variants. Funding: National Institute of Allergy and Infectious Diseases. |
| format | Article |
| id | doaj-art-312fbb1df2dc4adba1e3c906cf2f4809 |
| institution | Kabale University |
| issn | 2589-5370 |
| language | English |
| publishDate | 2025-02-01 |
| publisher | Elsevier |
| record_format | Article |
| series | EClinicalMedicine |
| spelling | doaj-art-312fbb1df2dc4adba1e3c906cf2f48092025-01-22T05:43:45ZengElsevierEClinicalMedicine2589-53702025-02-0180103054Hybrid versus vaccine immunity of mRNA-1273 among people living with HIV in East and Southern Africa: a prospective cohort analysis from the multicentre CoVPN 3008 (Ubuntu) studyResearch in contextNigel Garrett0Asa Tapley1Aaron Hudson2Sufia Dadabhai3Bo Zhang4Nyaradzo M. Mgodi5Jessica Andriesen6Azwidihwi Takalani7Leigh H. Fisher8Jia Jin Kee9Craig A. Magaret10Manuel Villaran11John Hural12Erica Andersen-Nissen13Guido Ferarri14Maurine D. Miner15Bert Le Roux16Eduan Wilkinson17Richard Lessells18Tulio de Oliveira19Jackline Odhiambo20Parth Shah21Laura Polakowski22Margaret Yacovone23Taraz Samandari24Zvavahera Chirenje25Peter James Elyanu26Joseph Makhema27Ethel Kamuti28Harriet Nuwagaba-Biribonwoha29Sharlaa Badal-Faesen30William Brumskine31Soritha Coetzer32Rodney Dawson33Sinead Delany-Moretlwe34Andreas Henri Diacon35Samantha Fry36Katherine Margaret Gill37Zaheer Ahmed Ebrahim Hoosain38Mina C. Hosseinipour39Mubiana Inambao40Craig Innes41Steve Innes42Dishiki Kalonji43Margaret Kasaro44Priya Kassim45Noel Kayange46William Kilembe47Fatima Laher48Moelo Malahleha49Vongane Louisa Maluleke50Grace Mboya51Kirsten McHarry52Essack Mitha53Kathryn Mngadi54Pamela Mda55Tumelo Moloantoa56Cissy Kityo Mutuluuza57Nivashnee Naicker58Vimla Naicker59Anusha Nana60Annet Nanvubya61Maphoshane Nchabeleng62Walter Otieno63Elsje Louise Potgieter64Disebo Potloane65Zelda Punt66Jamil Said67Yashna Singh68Mohammed Siddique Tayob69Yacoob Vahed70Deo Ogema Wabwire71M. Juliana McElrath72James G. Kublin73Linda-Gail Bekker74Peter B. Gilbert75Lawrence Corey76Glenda E. Gray77Yunda Huang78Philip Kotze79Sharlaa Badal-FaesenKagisho BaepanyeVeronique BaileyKatekani Baloyi-OsehMumtaz BooleyJohannes Louis BothaYolande BrownValerie BrownLisa BuntsSoritha CoetzerMyron CohenShirley CollieRodney DawsonPallabi DebHana El SahlyJill El-KhorazatyAndries EngelbrechtMarianne GildeaDhevium GovenderJen HankeJayla HarrisSimone HendricksNick HopkinsonHaley HowellNzeera KetterKentse KhutoFaatima Laher OmarLeolin KatsidziraKim LintonJames LudwigBongile MabilaneMatshidiso MalefoNdiitwani MamushianaDaciana MargineantuJeanine MayFatima MayatCindy MolitorYeshnee NaidooMichelle NebergallAlan NguyenSarah NiklesBianca NoronhaMelissa PedaTamara PhiriShanthie PillaySureshnee PillayLori Proulx-BurnsLaurie RinnLisa SandersCarrie SopherSmitha SripathyMichael StirewaltHouriiyah TegallySara ThiebaudAlicia ToledanoStephanie Van WykShamaya WhitbyStephany WilcoxEduan WilkinsonHaven WilvichCharles WiysongeNelisiwe XabaNtokozo XuluCentre for the AIDS Programme of Research in South Africa, University of KwaZulu–Natal, Durban, South Africa; Discipline of Public Health Medicine, School of Nursing and Public Health, University of KwaZulu-Natal, Durban, South Africa; Corresponding author. Centre for the AIDS Programme of Research in South Africa, University of KwaZulu-Natal, Durban, South Africa.Division of Allergy and Infectious Diseases, Department of Medicine, University of Washington, Seattle, USA; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, USA; Department of Medicine, University of Cape Town, Cape Town, South AfricaVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, USAJohns Hopkins Research Project, Blantyre, MalawiVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, USAClinical Trials Research Centre, University of Zimbabwe, Harare, ZimbabweVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, USAHutchinson Centre Research Institute of South Africa, Chris Hani Baragwanath Academic Hospital, Soweto, South AfricaVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, USAVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, USAVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, USAVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, USAVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, USAVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, USA; Cape Town HVTN Immunology Laboratory, Hutchinson Centre Research Institute of South Africa, Cape Town, South AfricaDuke University Human Vaccine Institute, Duke University School of Medicine, Durham, NC, USA; Center for HIV/AIDS Vaccine Immunology, Duke University School of Medicine, Durham, NC, USAVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, USAHutchinson Centre Research Institute of South Africa, Chris Hani Baragwanath Academic Hospital, Soweto, South AfricaKwaZulu-Natal Research Innovation & Sequencing Platform, School of Laboratory Medicine and Medical Sciences, University of KwaZulu-Natal, Durban, South Africa; Centre for Epidemic Response & Innovation, Stellenbosch, South AfricaKwaZulu-Natal Research Innovation & Sequencing Platform, School of Laboratory Medicine and Medical Sciences, University of KwaZulu-Natal, Durban, South AfricaKwaZulu-Natal Research Innovation & Sequencing Platform, School of Laboratory Medicine and Medical Sciences, University of KwaZulu-Natal, Durban, South Africa; Centre for Epidemic Response & Innovation, Stellenbosch, South AfricaVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, USA; Hutchinson Centre Research Institute of South Africa, Chris Hani Baragwanath Academic Hospital, Soweto, South AfricaPublic Health Sciences Division, Fred Hutchinson Cancer Center, Seattle, USANational Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, USANational Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, USACOVID-19 Prevention Network, Seattle, USAClinical Trials Research Centre, University of Zimbabwe, Harare, ZimbabweBaylor College of Medicine Children's Foundation-Uganda, Kampala, UgandaBotswana Harvard AIDS Institute, Gaborone, BotswanaCentre for Infectious Disease Research in Zambia, Lusaka, ZambiaICAP at Columbia University, Eswatini Prevention Center, Mbabane, Eswatini; Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, USAClinical HIV Research Unit/Helen Joseph Clinical Research Site, Johannesburg, South AfricaThe Aurum Institute, Rustenburg Clinical Research Site, Rustenburg, South AfricaSynexus Helderberg, Cape Town, South AfricaUniversity of Cape Town Lung Institute Clinical Research Site, Cape Town, South AfricaWits RHI University of the Witwatersrand, Johannesburg, South AfricaTASK Central, Cape Town, South AfricaFAMCRU Family Clinical Research Unit, Cape Town, South AfricaDesmond Tutu HIV Centre, University of Cape Town, Cape Town, South AfricaJosha Research Clinical Research Site, Bloemfontein, South AfricaMalawi Clinical Research Site, Lilongwe, Malawi; University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, USACFHRZ - Ndola Clinical Research Site, Ndola, ZambiaThe Aurum Institute, Klerksdorp Clinical Research Site, Klerksdorp, South AfricaDesmond Tutu HIV Centre, University of Cape Town, Cape Town, South AfricaSouth African Medical Research Council, Isipingo Clinical Research Site, KwaZulu-Natal, South AfricaUNC Global Projects/Kamwala District Health Centre, Lusaka, ZambiaSoweto - Kliptown Clinical Research Site, Soweto, South AfricaBlantyre Clinical Research Site, Blantyre, MalawiCFHRZ Clinical Research Site, Lusaka, ZambiaPerinatal HIV Research Unit, Faculty of Health Sciences, University of the Witwatersrand, South AfricaSynergy Biomed Research Institute, East London, South AfricaMERC Middelburg, Middelburg, South AfricaKisumu Clinical Research Site, Kisumu, KenyaTASK Eden, Western Cape, South AfricaNewtown Clinical Research, Johannesburg, South AfricaTembisa Clinic 4, Gauteng, South AfricaNelson Mandela Academic Clinical Research Unit Clinical Research Site, Mthatha, South AfricaPHRU Matlosana Clinical Research Site, Klerksdorp, South AfricaJoint Clinical Research Centre, Lubowa, UgandaCentre for the AIDS Programme of Research in South Africa, University of KwaZulu–Natal, Durban, South AfricaTongaat Clinical Research Site, KwaZulu-Natal, South AfricaSoweto - Kliptown Clinical Research Site, Soweto, South AfricaUVRI-IAVI HIV Vaccine Program Ltd. Clinical Research Site, Entebbe, UgandaMeCRU Clinical Research Site, Pretoria, South AfricaKombewa Clinical Research Site, Kisumu, Kenya; Maseno University School of Medicine, KenyaSynexus Stanza Clinical Research Centre Clinical Research Site, Pretoria, South AfricaCentre for the AIDS Programme of Research in South Africa, University of KwaZulu–Natal, Durban, South AfricaPHOENIX Pharma (Pty) Ltd, Port Elizabeth, South AfricaMoi University Clinical Research Centre, Eldoret, KenyaDesmond Tutu HIV Centre, University of Cape Town, Cape Town, South AfricaMERC Kempton, Kempton, South AfricaMERC Welkom, Welkom, South AfricaMU-JHU Research Collaboration Clinical Research Site, Kampala, UgandaVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, USAVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, USADesmond Tutu HIV Centre, University of Cape Town, Cape Town, South AfricaVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, USAVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, USASouth African Medical Research Council, Pretoria, South AfricaVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, USA; Department of Global Health, University of Washington, Seattle, USAQhakaza Mbokodo Research Clinic, Ladysmith, South AfricaSummary: Background: With limited access to mRNA COVID-19 vaccines in lower income countries, and people living with HIV (PLWH) largely excluded from clinical trials, Part A of the multicentre CoVPN 3008 (Ubuntu) study aimed to assess the safety of mRNA-1273, the relative effectiveness of hybrid versus vaccine immunity, and SARS-CoV-2 viral persistence among PLWH in East and Southern Africa during the omicron outbreak. Methods: Previously unvaccinated adults with HIV and/or other comorbidities associated with severe COVID-19 received either one (hybrid immunity) or two (vaccine immunity) 100-mcg doses of ancestral strain mRNA-1273 in the first month, depending on baseline evidence of prior SARS-CoV-2 infection. In a prospective cohort study design, we used covariate-adjusted Cox regression and counterfactual cumulative incidence methods to determine the hazard ratio and relative risk of COVID-19 and severe COVID-19 with hybrid versus vaccine immunity within six months. The ongoing Ubuntu study is registered on ClinicalTrials.gov (NCT05168813) and this work was conducted from December 2021 to March 2023. Findings: Between December 2021 and September 2022, 14,237 participants enrolled, and 14,002 (83% PLWH, 69% SARS-CoV-2 seropositive) were included in the analyses. Vaccinations were safe and well tolerated. Common adverse events were pain or tenderness at the injection site (26.7%), headache (20.4%), and malaise (20.3%). Severe adverse events were rare (0.8% of participants after the first and 1.1% after the second vaccination), and none were life-threatening or fatal. Among PLWH, the median CD4 count was 635 cells/μl and 18.5% had HIV viraemia. The six-month cumulative incidences in the hybrid immunity and vaccine immunity groups were 2.02% (95% confidence interval [CI] 1.61–2.44) and 3.40% (95% CI 2.30–4.49) for COVID-19, and 0.048% (95% CI 0.00–0.10) and 0.32% (95% CI 0.59–0.63) for severe COVID-19. Among all PLWH the hybrid immunity group had a 42% lower hazard rate of COVID-19 (hazard ratio [HR] 0.58; 95% CI 0.44–0.77; p < 0.001) and a 73% lower hazard rate of severe COVID-19 (HR 0.27; 95% CI 0.07–1.04; p = 0.056) than the vaccine immunity group, but this effect was not seen among PLWH with CD4 counts <350 cells/μl or HIV viraemia. Twenty PLWH had persistent SARS-CoV-2 virus at least 50 days. Interpretation: Hybrid immunity was associated with superior protection from COVID-19 compared to vaccine immunity with the ancestral mRNA-1273 vaccine. Persistent infections among immunocompromised PLWH may provide reservoirs for emerging variants. Funding: National Institute of Allergy and Infectious Diseases.http://www.sciencedirect.com/science/article/pii/S2589537024006333People living with HIVSARS-CoV-2mRNA-1273Hybrid immunityVaccine immunityCOVID-19 |
| spellingShingle | Nigel Garrett Asa Tapley Aaron Hudson Sufia Dadabhai Bo Zhang Nyaradzo M. Mgodi Jessica Andriesen Azwidihwi Takalani Leigh H. Fisher Jia Jin Kee Craig A. Magaret Manuel Villaran John Hural Erica Andersen-Nissen Guido Ferarri Maurine D. Miner Bert Le Roux Eduan Wilkinson Richard Lessells Tulio de Oliveira Jackline Odhiambo Parth Shah Laura Polakowski Margaret Yacovone Taraz Samandari Zvavahera Chirenje Peter James Elyanu Joseph Makhema Ethel Kamuti Harriet Nuwagaba-Biribonwoha Sharlaa Badal-Faesen William Brumskine Soritha Coetzer Rodney Dawson Sinead Delany-Moretlwe Andreas Henri Diacon Samantha Fry Katherine Margaret Gill Zaheer Ahmed Ebrahim Hoosain Mina C. Hosseinipour Mubiana Inambao Craig Innes Steve Innes Dishiki Kalonji Margaret Kasaro Priya Kassim Noel Kayange William Kilembe Fatima Laher Moelo Malahleha Vongane Louisa Maluleke Grace Mboya Kirsten McHarry Essack Mitha Kathryn Mngadi Pamela Mda Tumelo Moloantoa Cissy Kityo Mutuluuza Nivashnee Naicker Vimla Naicker Anusha Nana Annet Nanvubya Maphoshane Nchabeleng Walter Otieno Elsje Louise Potgieter Disebo Potloane Zelda Punt Jamil Said Yashna Singh Mohammed Siddique Tayob Yacoob Vahed Deo Ogema Wabwire M. Juliana McElrath James G. Kublin Linda-Gail Bekker Peter B. Gilbert Lawrence Corey Glenda E. Gray Yunda Huang Philip Kotze Sharlaa Badal-Faesen Kagisho Baepanye Veronique Bailey Katekani Baloyi-Oseh Mumtaz Booley Johannes Louis Botha Yolande Brown Valerie Brown Lisa Bunts Soritha Coetzer Myron Cohen Shirley Collie Rodney Dawson Pallabi Deb Hana El Sahly Jill El-Khorazaty Andries Engelbrecht Marianne Gildea Dhevium Govender Jen Hanke Jayla Harris Simone Hendricks Nick Hopkinson Haley Howell Nzeera Ketter Kentse Khuto Faatima Laher Omar Leolin Katsidzira Kim Linton James Ludwig Bongile Mabilane Matshidiso Malefo Ndiitwani Mamushiana Daciana Margineantu Jeanine May Fatima Mayat Cindy Molitor Yeshnee Naidoo Michelle Nebergall Alan Nguyen Sarah Nikles Bianca Noronha Melissa Peda Tamara Phiri Shanthie Pillay Sureshnee Pillay Lori Proulx-Burns Laurie Rinn Lisa Sanders Carrie Sopher Smitha Sripathy Michael Stirewalt Houriiyah Tegally Sara Thiebaud Alicia Toledano Stephanie Van Wyk Shamaya Whitby Stephany Wilcox Eduan Wilkinson Haven Wilvich Charles Wiysonge Nelisiwe Xaba Ntokozo Xulu Hybrid versus vaccine immunity of mRNA-1273 among people living with HIV in East and Southern Africa: a prospective cohort analysis from the multicentre CoVPN 3008 (Ubuntu) studyResearch in context EClinicalMedicine People living with HIV SARS-CoV-2 mRNA-1273 Hybrid immunity Vaccine immunity COVID-19 |
| title | Hybrid versus vaccine immunity of mRNA-1273 among people living with HIV in East and Southern Africa: a prospective cohort analysis from the multicentre CoVPN 3008 (Ubuntu) studyResearch in context |
| title_full | Hybrid versus vaccine immunity of mRNA-1273 among people living with HIV in East and Southern Africa: a prospective cohort analysis from the multicentre CoVPN 3008 (Ubuntu) studyResearch in context |
| title_fullStr | Hybrid versus vaccine immunity of mRNA-1273 among people living with HIV in East and Southern Africa: a prospective cohort analysis from the multicentre CoVPN 3008 (Ubuntu) studyResearch in context |
| title_full_unstemmed | Hybrid versus vaccine immunity of mRNA-1273 among people living with HIV in East and Southern Africa: a prospective cohort analysis from the multicentre CoVPN 3008 (Ubuntu) studyResearch in context |
| title_short | Hybrid versus vaccine immunity of mRNA-1273 among people living with HIV in East and Southern Africa: a prospective cohort analysis from the multicentre CoVPN 3008 (Ubuntu) studyResearch in context |
| title_sort | hybrid versus vaccine immunity of mrna 1273 among people living with hiv in east and southern africa a prospective cohort analysis from the multicentre covpn 3008 ubuntu studyresearch in context |
| topic | People living with HIV SARS-CoV-2 mRNA-1273 Hybrid immunity Vaccine immunity COVID-19 |
| url | http://www.sciencedirect.com/science/article/pii/S2589537024006333 |
| work_keys_str_mv | AT nigelgarrett hybridversusvaccineimmunityofmrna1273amongpeoplelivingwithhivineastandsouthernafricaaprospectivecohortanalysisfromthemulticentrecovpn3008ubuntustudyresearchincontext AT asatapley hybridversusvaccineimmunityofmrna1273amongpeoplelivingwithhivineastandsouthernafricaaprospectivecohortanalysisfromthemulticentrecovpn3008ubuntustudyresearchincontext AT aaronhudson hybridversusvaccineimmunityofmrna1273amongpeoplelivingwithhivineastandsouthernafricaaprospectivecohortanalysisfromthemulticentrecovpn3008ubuntustudyresearchincontext AT sufiadadabhai hybridversusvaccineimmunityofmrna1273amongpeoplelivingwithhivineastandsouthernafricaaprospectivecohortanalysisfromthemulticentrecovpn3008ubuntustudyresearchincontext AT bozhang hybridversusvaccineimmunityofmrna1273amongpeoplelivingwithhivineastandsouthernafricaaprospectivecohortanalysisfromthemulticentrecovpn3008ubuntustudyresearchincontext AT nyaradzommgodi hybridversusvaccineimmunityofmrna1273amongpeoplelivingwithhivineastandsouthernafricaaprospectivecohortanalysisfromthemulticentrecovpn3008ubuntustudyresearchincontext AT jessicaandriesen hybridversusvaccineimmunityofmrna1273amongpeoplelivingwithhivineastandsouthernafricaaprospectivecohortanalysisfromthemulticentrecovpn3008ubuntustudyresearchincontext AT azwidihwitakalani hybridversusvaccineimmunityofmrna1273amongpeoplelivingwithhivineastandsouthernafricaaprospectivecohortanalysisfromthemulticentrecovpn3008ubuntustudyresearchincontext AT leighhfisher hybridversusvaccineimmunityofmrna1273amongpeoplelivingwithhivineastandsouthernafricaaprospectivecohortanalysisfromthemulticentrecovpn3008ubuntustudyresearchincontext AT jiajinkee hybridversusvaccineimmunityofmrna1273amongpeoplelivingwithhivineastandsouthernafricaaprospectivecohortanalysisfromthemulticentrecovpn3008ubuntustudyresearchincontext AT craigamagaret hybridversusvaccineimmunityofmrna1273amongpeoplelivingwithhivineastandsouthernafricaaprospectivecohortanalysisfromthemulticentrecovpn3008ubuntustudyresearchincontext AT manuelvillaran hybridversusvaccineimmunityofmrna1273amongpeoplelivingwithhivineastandsouthernafricaaprospectivecohortanalysisfromthemulticentrecovpn3008ubuntustudyresearchincontext AT johnhural hybridversusvaccineimmunityofmrna1273amongpeoplelivingwithhivineastandsouthernafricaaprospectivecohortanalysisfromthemulticentrecovpn3008ubuntustudyresearchincontext AT ericaandersennissen hybridversusvaccineimmunityofmrna1273amongpeoplelivingwithhivineastandsouthernafricaaprospectivecohortanalysisfromthemulticentrecovpn3008ubuntustudyresearchincontext AT guidoferarri hybridversusvaccineimmunityofmrna1273amongpeoplelivingwithhivineastandsouthernafricaaprospectivecohortanalysisfromthemulticentrecovpn3008ubuntustudyresearchincontext AT maurinedminer hybridversusvaccineimmunityofmrna1273amongpeoplelivingwithhivineastandsouthernafricaaprospectivecohortanalysisfromthemulticentrecovpn3008ubuntustudyresearchincontext AT bertleroux hybridversusvaccineimmunityofmrna1273amongpeoplelivingwithhivineastandsouthernafricaaprospectivecohortanalysisfromthemulticentrecovpn3008ubuntustudyresearchincontext AT eduanwilkinson hybridversusvaccineimmunityofmrna1273amongpeoplelivingwithhivineastandsouthernafricaaprospectivecohortanalysisfromthemulticentrecovpn3008ubuntustudyresearchincontext AT richardlessells hybridversusvaccineimmunityofmrna1273amongpeoplelivingwithhivineastandsouthernafricaaprospectivecohortanalysisfromthemulticentrecovpn3008ubuntustudyresearchincontext AT tuliodeoliveira hybridversusvaccineimmunityofmrna1273amongpeoplelivingwithhivineastandsouthernafricaaprospectivecohortanalysisfromthemulticentrecovpn3008ubuntustudyresearchincontext AT jacklineodhiambo hybridversusvaccineimmunityofmrna1273amongpeoplelivingwithhivineastandsouthernafricaaprospectivecohortanalysisfromthemulticentrecovpn3008ubuntustudyresearchincontext AT parthshah hybridversusvaccineimmunityofmrna1273amongpeoplelivingwithhivineastandsouthernafricaaprospectivecohortanalysisfromthemulticentrecovpn3008ubuntustudyresearchincontext AT laurapolakowski hybridversusvaccineimmunityofmrna1273amongpeoplelivingwithhivineastandsouthernafricaaprospectivecohortanalysisfromthemulticentrecovpn3008ubuntustudyresearchincontext AT margaretyacovone hybridversusvaccineimmunityofmrna1273amongpeoplelivingwithhivineastandsouthernafricaaprospectivecohortanalysisfromthemulticentrecovpn3008ubuntustudyresearchincontext AT tarazsamandari hybridversusvaccineimmunityofmrna1273amongpeoplelivingwithhivineastandsouthernafricaaprospectivecohortanalysisfromthemulticentrecovpn3008ubuntustudyresearchincontext AT zvavaherachirenje hybridversusvaccineimmunityofmrna1273amongpeoplelivingwithhivineastandsouthernafricaaprospectivecohortanalysisfromthemulticentrecovpn3008ubuntustudyresearchincontext AT peterjameselyanu hybridversusvaccineimmunityofmrna1273amongpeoplelivingwithhivineastandsouthernafricaaprospectivecohortanalysisfromthemulticentrecovpn3008ubuntustudyresearchincontext AT josephmakhema hybridversusvaccineimmunityofmrna1273amongpeoplelivingwithhivineastandsouthernafricaaprospectivecohortanalysisfromthemulticentrecovpn3008ubuntustudyresearchincontext AT ethelkamuti hybridversusvaccineimmunityofmrna1273amongpeoplelivingwithhivineastandsouthernafricaaprospectivecohortanalysisfromthemulticentrecovpn3008ubuntustudyresearchincontext AT harrietnuwagababiribonwoha hybridversusvaccineimmunityofmrna1273amongpeoplelivingwithhivineastandsouthernafricaaprospectivecohortanalysisfromthemulticentrecovpn3008ubuntustudyresearchincontext AT sharlaabadalfaesen hybridversusvaccineimmunityofmrna1273amongpeoplelivingwithhivineastandsouthernafricaaprospectivecohortanalysisfromthemulticentrecovpn3008ubuntustudyresearchincontext AT williambrumskine hybridversusvaccineimmunityofmrna1273amongpeoplelivingwithhivineastandsouthernafricaaprospectivecohortanalysisfromthemulticentrecovpn3008ubuntustudyresearchincontext AT sorithacoetzer hybridversusvaccineimmunityofmrna1273amongpeoplelivingwithhivineastandsouthernafricaaprospectivecohortanalysisfromthemulticentrecovpn3008ubuntustudyresearchincontext AT rodneydawson hybridversusvaccineimmunityofmrna1273amongpeoplelivingwithhivineastandsouthernafricaaprospectivecohortanalysisfromthemulticentrecovpn3008ubuntustudyresearchincontext AT sineaddelanymoretlwe hybridversusvaccineimmunityofmrna1273amongpeoplelivingwithhivineastandsouthernafricaaprospectivecohortanalysisfromthemulticentrecovpn3008ubuntustudyresearchincontext AT andreashenridiacon hybridversusvaccineimmunityofmrna1273amongpeoplelivingwithhivineastandsouthernafricaaprospectivecohortanalysisfromthemulticentrecovpn3008ubuntustudyresearchincontext AT samanthafry hybridversusvaccineimmunityofmrna1273amongpeoplelivingwithhivineastandsouthernafricaaprospectivecohortanalysisfromthemulticentrecovpn3008ubuntustudyresearchincontext AT katherinemargaretgill hybridversusvaccineimmunityofmrna1273amongpeoplelivingwithhivineastandsouthernafricaaprospectivecohortanalysisfromthemulticentrecovpn3008ubuntustudyresearchincontext AT zaheerahmedebrahimhoosain hybridversusvaccineimmunityofmrna1273amongpeoplelivingwithhivineastandsouthernafricaaprospectivecohortanalysisfromthemulticentrecovpn3008ubuntustudyresearchincontext AT minachosseinipour hybridversusvaccineimmunityofmrna1273amongpeoplelivingwithhivineastandsouthernafricaaprospectivecohortanalysisfromthemulticentrecovpn3008ubuntustudyresearchincontext AT mubianainambao hybridversusvaccineimmunityofmrna1273amongpeoplelivingwithhivineastandsouthernafricaaprospectivecohortanalysisfromthemulticentrecovpn3008ubuntustudyresearchincontext AT craiginnes hybridversusvaccineimmunityofmrna1273amongpeoplelivingwithhivineastandsouthernafricaaprospectivecohortanalysisfromthemulticentrecovpn3008ubuntustudyresearchincontext AT steveinnes hybridversusvaccineimmunityofmrna1273amongpeoplelivingwithhivineastandsouthernafricaaprospectivecohortanalysisfromthemulticentrecovpn3008ubuntustudyresearchincontext AT dishikikalonji hybridversusvaccineimmunityofmrna1273amongpeoplelivingwithhivineastandsouthernafricaaprospectivecohortanalysisfromthemulticentrecovpn3008ubuntustudyresearchincontext AT margaretkasaro hybridversusvaccineimmunityofmrna1273amongpeoplelivingwithhivineastandsouthernafricaaprospectivecohortanalysisfromthemulticentrecovpn3008ubuntustudyresearchincontext AT priyakassim hybridversusvaccineimmunityofmrna1273amongpeoplelivingwithhivineastandsouthernafricaaprospectivecohortanalysisfromthemulticentrecovpn3008ubuntustudyresearchincontext AT noelkayange hybridversusvaccineimmunityofmrna1273amongpeoplelivingwithhivineastandsouthernafricaaprospectivecohortanalysisfromthemulticentrecovpn3008ubuntustudyresearchincontext AT williamkilembe hybridversusvaccineimmunityofmrna1273amongpeoplelivingwithhivineastandsouthernafricaaprospectivecohortanalysisfromthemulticentrecovpn3008ubuntustudyresearchincontext AT fatimalaher hybridversusvaccineimmunityofmrna1273amongpeoplelivingwithhivineastandsouthernafricaaprospectivecohortanalysisfromthemulticentrecovpn3008ubuntustudyresearchincontext AT moelomalahleha hybridversusvaccineimmunityofmrna1273amongpeoplelivingwithhivineastandsouthernafricaaprospectivecohortanalysisfromthemulticentrecovpn3008ubuntustudyresearchincontext AT vonganelouisamaluleke hybridversusvaccineimmunityofmrna1273amongpeoplelivingwithhivineastandsouthernafricaaprospectivecohortanalysisfromthemulticentrecovpn3008ubuntustudyresearchincontext AT gracemboya hybridversusvaccineimmunityofmrna1273amongpeoplelivingwithhivineastandsouthernafricaaprospectivecohortanalysisfromthemulticentrecovpn3008ubuntustudyresearchincontext AT kirstenmcharry hybridversusvaccineimmunityofmrna1273amongpeoplelivingwithhivineastandsouthernafricaaprospectivecohortanalysisfromthemulticentrecovpn3008ubuntustudyresearchincontext AT essackmitha hybridversusvaccineimmunityofmrna1273amongpeoplelivingwithhivineastandsouthernafricaaprospectivecohortanalysisfromthemulticentrecovpn3008ubuntustudyresearchincontext AT kathrynmngadi hybridversusvaccineimmunityofmrna1273amongpeoplelivingwithhivineastandsouthernafricaaprospectivecohortanalysisfromthemulticentrecovpn3008ubuntustudyresearchincontext AT pamelamda hybridversusvaccineimmunityofmrna1273amongpeoplelivingwithhivineastandsouthernafricaaprospectivecohortanalysisfromthemulticentrecovpn3008ubuntustudyresearchincontext AT tumelomoloantoa hybridversusvaccineimmunityofmrna1273amongpeoplelivingwithhivineastandsouthernafricaaprospectivecohortanalysisfromthemulticentrecovpn3008ubuntustudyresearchincontext AT cissykityomutuluuza hybridversusvaccineimmunityofmrna1273amongpeoplelivingwithhivineastandsouthernafricaaprospectivecohortanalysisfromthemulticentrecovpn3008ubuntustudyresearchincontext AT nivashneenaicker hybridversusvaccineimmunityofmrna1273amongpeoplelivingwithhivineastandsouthernafricaaprospectivecohortanalysisfromthemulticentrecovpn3008ubuntustudyresearchincontext AT vimlanaicker hybridversusvaccineimmunityofmrna1273amongpeoplelivingwithhivineastandsouthernafricaaprospectivecohortanalysisfromthemulticentrecovpn3008ubuntustudyresearchincontext AT anushanana hybridversusvaccineimmunityofmrna1273amongpeoplelivingwithhivineastandsouthernafricaaprospectivecohortanalysisfromthemulticentrecovpn3008ubuntustudyresearchincontext AT annetnanvubya hybridversusvaccineimmunityofmrna1273amongpeoplelivingwithhivineastandsouthernafricaaprospectivecohortanalysisfromthemulticentrecovpn3008ubuntustudyresearchincontext AT maphoshanenchabeleng hybridversusvaccineimmunityofmrna1273amongpeoplelivingwithhivineastandsouthernafricaaprospectivecohortanalysisfromthemulticentrecovpn3008ubuntustudyresearchincontext AT walterotieno hybridversusvaccineimmunityofmrna1273amongpeoplelivingwithhivineastandsouthernafricaaprospectivecohortanalysisfromthemulticentrecovpn3008ubuntustudyresearchincontext AT elsjelouisepotgieter hybridversusvaccineimmunityofmrna1273amongpeoplelivingwithhivineastandsouthernafricaaprospectivecohortanalysisfromthemulticentrecovpn3008ubuntustudyresearchincontext AT disebopotloane hybridversusvaccineimmunityofmrna1273amongpeoplelivingwithhivineastandsouthernafricaaprospectivecohortanalysisfromthemulticentrecovpn3008ubuntustudyresearchincontext AT zeldapunt hybridversusvaccineimmunityofmrna1273amongpeoplelivingwithhivineastandsouthernafricaaprospectivecohortanalysisfromthemulticentrecovpn3008ubuntustudyresearchincontext AT jamilsaid hybridversusvaccineimmunityofmrna1273amongpeoplelivingwithhivineastandsouthernafricaaprospectivecohortanalysisfromthemulticentrecovpn3008ubuntustudyresearchincontext AT yashnasingh hybridversusvaccineimmunityofmrna1273amongpeoplelivingwithhivineastandsouthernafricaaprospectivecohortanalysisfromthemulticentrecovpn3008ubuntustudyresearchincontext AT mohammedsiddiquetayob hybridversusvaccineimmunityofmrna1273amongpeoplelivingwithhivineastandsouthernafricaaprospectivecohortanalysisfromthemulticentrecovpn3008ubuntustudyresearchincontext AT yacoobvahed hybridversusvaccineimmunityofmrna1273amongpeoplelivingwithhivineastandsouthernafricaaprospectivecohortanalysisfromthemulticentrecovpn3008ubuntustudyresearchincontext AT deoogemawabwire hybridversusvaccineimmunityofmrna1273amongpeoplelivingwithhivineastandsouthernafricaaprospectivecohortanalysisfromthemulticentrecovpn3008ubuntustudyresearchincontext AT mjulianamcelrath hybridversusvaccineimmunityofmrna1273amongpeoplelivingwithhivineastandsouthernafricaaprospectivecohortanalysisfromthemulticentrecovpn3008ubuntustudyresearchincontext AT jamesgkublin hybridversusvaccineimmunityofmrna1273amongpeoplelivingwithhivineastandsouthernafricaaprospectivecohortanalysisfromthemulticentrecovpn3008ubuntustudyresearchincontext AT lindagailbekker hybridversusvaccineimmunityofmrna1273amongpeoplelivingwithhivineastandsouthernafricaaprospectivecohortanalysisfromthemulticentrecovpn3008ubuntustudyresearchincontext AT peterbgilbert hybridversusvaccineimmunityofmrna1273amongpeoplelivingwithhivineastandsouthernafricaaprospectivecohortanalysisfromthemulticentrecovpn3008ubuntustudyresearchincontext AT lawrencecorey hybridversusvaccineimmunityofmrna1273amongpeoplelivingwithhivineastandsouthernafricaaprospectivecohortanalysisfromthemulticentrecovpn3008ubuntustudyresearchincontext AT glendaegray hybridversusvaccineimmunityofmrna1273amongpeoplelivingwithhivineastandsouthernafricaaprospectivecohortanalysisfromthemulticentrecovpn3008ubuntustudyresearchincontext AT yundahuang hybridversusvaccineimmunityofmrna1273amongpeoplelivingwithhivineastandsouthernafricaaprospectivecohortanalysisfromthemulticentrecovpn3008ubuntustudyresearchincontext AT philipkotze hybridversusvaccineimmunityofmrna1273amongpeoplelivingwithhivineastandsouthernafricaaprospectivecohortanalysisfromthemulticentrecovpn3008ubuntustudyresearchincontext AT sharlaabadalfaesen hybridversusvaccineimmunityofmrna1273amongpeoplelivingwithhivineastandsouthernafricaaprospectivecohortanalysisfromthemulticentrecovpn3008ubuntustudyresearchincontext AT kagishobaepanye hybridversusvaccineimmunityofmrna1273amongpeoplelivingwithhivineastandsouthernafricaaprospectivecohortanalysisfromthemulticentrecovpn3008ubuntustudyresearchincontext AT veroniquebailey hybridversusvaccineimmunityofmrna1273amongpeoplelivingwithhivineastandsouthernafricaaprospectivecohortanalysisfromthemulticentrecovpn3008ubuntustudyresearchincontext AT katekanibaloyioseh hybridversusvaccineimmunityofmrna1273amongpeoplelivingwithhivineastandsouthernafricaaprospectivecohortanalysisfromthemulticentrecovpn3008ubuntustudyresearchincontext AT mumtazbooley hybridversusvaccineimmunityofmrna1273amongpeoplelivingwithhivineastandsouthernafricaaprospectivecohortanalysisfromthemulticentrecovpn3008ubuntustudyresearchincontext AT johanneslouisbotha hybridversusvaccineimmunityofmrna1273amongpeoplelivingwithhivineastandsouthernafricaaprospectivecohortanalysisfromthemulticentrecovpn3008ubuntustudyresearchincontext AT yolandebrown hybridversusvaccineimmunityofmrna1273amongpeoplelivingwithhivineastandsouthernafricaaprospectivecohortanalysisfromthemulticentrecovpn3008ubuntustudyresearchincontext AT valeriebrown hybridversusvaccineimmunityofmrna1273amongpeoplelivingwithhivineastandsouthernafricaaprospectivecohortanalysisfromthemulticentrecovpn3008ubuntustudyresearchincontext AT lisabunts hybridversusvaccineimmunityofmrna1273amongpeoplelivingwithhivineastandsouthernafricaaprospectivecohortanalysisfromthemulticentrecovpn3008ubuntustudyresearchincontext AT sorithacoetzer hybridversusvaccineimmunityofmrna1273amongpeoplelivingwithhivineastandsouthernafricaaprospectivecohortanalysisfromthemulticentrecovpn3008ubuntustudyresearchincontext AT myroncohen hybridversusvaccineimmunityofmrna1273amongpeoplelivingwithhivineastandsouthernafricaaprospectivecohortanalysisfromthemulticentrecovpn3008ubuntustudyresearchincontext AT shirleycollie hybridversusvaccineimmunityofmrna1273amongpeoplelivingwithhivineastandsouthernafricaaprospectivecohortanalysisfromthemulticentrecovpn3008ubuntustudyresearchincontext AT rodneydawson hybridversusvaccineimmunityofmrna1273amongpeoplelivingwithhivineastandsouthernafricaaprospectivecohortanalysisfromthemulticentrecovpn3008ubuntustudyresearchincontext AT pallabideb hybridversusvaccineimmunityofmrna1273amongpeoplelivingwithhivineastandsouthernafricaaprospectivecohortanalysisfromthemulticentrecovpn3008ubuntustudyresearchincontext AT hanaelsahly hybridversusvaccineimmunityofmrna1273amongpeoplelivingwithhivineastandsouthernafricaaprospectivecohortanalysisfromthemulticentrecovpn3008ubuntustudyresearchincontext AT jillelkhorazaty hybridversusvaccineimmunityofmrna1273amongpeoplelivingwithhivineastandsouthernafricaaprospectivecohortanalysisfromthemulticentrecovpn3008ubuntustudyresearchincontext AT andriesengelbrecht hybridversusvaccineimmunityofmrna1273amongpeoplelivingwithhivineastandsouthernafricaaprospectivecohortanalysisfromthemulticentrecovpn3008ubuntustudyresearchincontext AT mariannegildea hybridversusvaccineimmunityofmrna1273amongpeoplelivingwithhivineastandsouthernafricaaprospectivecohortanalysisfromthemulticentrecovpn3008ubuntustudyresearchincontext AT dheviumgovender hybridversusvaccineimmunityofmrna1273amongpeoplelivingwithhivineastandsouthernafricaaprospectivecohortanalysisfromthemulticentrecovpn3008ubuntustudyresearchincontext AT jenhanke hybridversusvaccineimmunityofmrna1273amongpeoplelivingwithhivineastandsouthernafricaaprospectivecohortanalysisfromthemulticentrecovpn3008ubuntustudyresearchincontext AT jaylaharris hybridversusvaccineimmunityofmrna1273amongpeoplelivingwithhivineastandsouthernafricaaprospectivecohortanalysisfromthemulticentrecovpn3008ubuntustudyresearchincontext AT simonehendricks hybridversusvaccineimmunityofmrna1273amongpeoplelivingwithhivineastandsouthernafricaaprospectivecohortanalysisfromthemulticentrecovpn3008ubuntustudyresearchincontext AT nickhopkinson hybridversusvaccineimmunityofmrna1273amongpeoplelivingwithhivineastandsouthernafricaaprospectivecohortanalysisfromthemulticentrecovpn3008ubuntustudyresearchincontext AT haleyhowell hybridversusvaccineimmunityofmrna1273amongpeoplelivingwithhivineastandsouthernafricaaprospectivecohortanalysisfromthemulticentrecovpn3008ubuntustudyresearchincontext AT nzeeraketter hybridversusvaccineimmunityofmrna1273amongpeoplelivingwithhivineastandsouthernafricaaprospectivecohortanalysisfromthemulticentrecovpn3008ubuntustudyresearchincontext AT kentsekhuto hybridversusvaccineimmunityofmrna1273amongpeoplelivingwithhivineastandsouthernafricaaprospectivecohortanalysisfromthemulticentrecovpn3008ubuntustudyresearchincontext AT faatimalaheromar hybridversusvaccineimmunityofmrna1273amongpeoplelivingwithhivineastandsouthernafricaaprospectivecohortanalysisfromthemulticentrecovpn3008ubuntustudyresearchincontext AT leolinkatsidzira hybridversusvaccineimmunityofmrna1273amongpeoplelivingwithhivineastandsouthernafricaaprospectivecohortanalysisfromthemulticentrecovpn3008ubuntustudyresearchincontext AT kimlinton hybridversusvaccineimmunityofmrna1273amongpeoplelivingwithhivineastandsouthernafricaaprospectivecohortanalysisfromthemulticentrecovpn3008ubuntustudyresearchincontext AT jamesludwig hybridversusvaccineimmunityofmrna1273amongpeoplelivingwithhivineastandsouthernafricaaprospectivecohortanalysisfromthemulticentrecovpn3008ubuntustudyresearchincontext AT bongilemabilane hybridversusvaccineimmunityofmrna1273amongpeoplelivingwithhivineastandsouthernafricaaprospectivecohortanalysisfromthemulticentrecovpn3008ubuntustudyresearchincontext AT matshidisomalefo hybridversusvaccineimmunityofmrna1273amongpeoplelivingwithhivineastandsouthernafricaaprospectivecohortanalysisfromthemulticentrecovpn3008ubuntustudyresearchincontext AT ndiitwanimamushiana hybridversusvaccineimmunityofmrna1273amongpeoplelivingwithhivineastandsouthernafricaaprospectivecohortanalysisfromthemulticentrecovpn3008ubuntustudyresearchincontext AT dacianamargineantu hybridversusvaccineimmunityofmrna1273amongpeoplelivingwithhivineastandsouthernafricaaprospectivecohortanalysisfromthemulticentrecovpn3008ubuntustudyresearchincontext AT jeaninemay hybridversusvaccineimmunityofmrna1273amongpeoplelivingwithhivineastandsouthernafricaaprospectivecohortanalysisfromthemulticentrecovpn3008ubuntustudyresearchincontext AT fatimamayat hybridversusvaccineimmunityofmrna1273amongpeoplelivingwithhivineastandsouthernafricaaprospectivecohortanalysisfromthemulticentrecovpn3008ubuntustudyresearchincontext AT cindymolitor hybridversusvaccineimmunityofmrna1273amongpeoplelivingwithhivineastandsouthernafricaaprospectivecohortanalysisfromthemulticentrecovpn3008ubuntustudyresearchincontext AT yeshneenaidoo hybridversusvaccineimmunityofmrna1273amongpeoplelivingwithhivineastandsouthernafricaaprospectivecohortanalysisfromthemulticentrecovpn3008ubuntustudyresearchincontext AT michellenebergall hybridversusvaccineimmunityofmrna1273amongpeoplelivingwithhivineastandsouthernafricaaprospectivecohortanalysisfromthemulticentrecovpn3008ubuntustudyresearchincontext AT alannguyen hybridversusvaccineimmunityofmrna1273amongpeoplelivingwithhivineastandsouthernafricaaprospectivecohortanalysisfromthemulticentrecovpn3008ubuntustudyresearchincontext AT sarahnikles hybridversusvaccineimmunityofmrna1273amongpeoplelivingwithhivineastandsouthernafricaaprospectivecohortanalysisfromthemulticentrecovpn3008ubuntustudyresearchincontext AT biancanoronha hybridversusvaccineimmunityofmrna1273amongpeoplelivingwithhivineastandsouthernafricaaprospectivecohortanalysisfromthemulticentrecovpn3008ubuntustudyresearchincontext AT melissapeda hybridversusvaccineimmunityofmrna1273amongpeoplelivingwithhivineastandsouthernafricaaprospectivecohortanalysisfromthemulticentrecovpn3008ubuntustudyresearchincontext AT tamaraphiri hybridversusvaccineimmunityofmrna1273amongpeoplelivingwithhivineastandsouthernafricaaprospectivecohortanalysisfromthemulticentrecovpn3008ubuntustudyresearchincontext AT shanthiepillay hybridversusvaccineimmunityofmrna1273amongpeoplelivingwithhivineastandsouthernafricaaprospectivecohortanalysisfromthemulticentrecovpn3008ubuntustudyresearchincontext AT sureshneepillay hybridversusvaccineimmunityofmrna1273amongpeoplelivingwithhivineastandsouthernafricaaprospectivecohortanalysisfromthemulticentrecovpn3008ubuntustudyresearchincontext AT loriproulxburns hybridversusvaccineimmunityofmrna1273amongpeoplelivingwithhivineastandsouthernafricaaprospectivecohortanalysisfromthemulticentrecovpn3008ubuntustudyresearchincontext AT laurierinn hybridversusvaccineimmunityofmrna1273amongpeoplelivingwithhivineastandsouthernafricaaprospectivecohortanalysisfromthemulticentrecovpn3008ubuntustudyresearchincontext AT lisasanders hybridversusvaccineimmunityofmrna1273amongpeoplelivingwithhivineastandsouthernafricaaprospectivecohortanalysisfromthemulticentrecovpn3008ubuntustudyresearchincontext AT carriesopher hybridversusvaccineimmunityofmrna1273amongpeoplelivingwithhivineastandsouthernafricaaprospectivecohortanalysisfromthemulticentrecovpn3008ubuntustudyresearchincontext AT smithasripathy hybridversusvaccineimmunityofmrna1273amongpeoplelivingwithhivineastandsouthernafricaaprospectivecohortanalysisfromthemulticentrecovpn3008ubuntustudyresearchincontext AT michaelstirewalt hybridversusvaccineimmunityofmrna1273amongpeoplelivingwithhivineastandsouthernafricaaprospectivecohortanalysisfromthemulticentrecovpn3008ubuntustudyresearchincontext AT houriiyahtegally hybridversusvaccineimmunityofmrna1273amongpeoplelivingwithhivineastandsouthernafricaaprospectivecohortanalysisfromthemulticentrecovpn3008ubuntustudyresearchincontext AT sarathiebaud hybridversusvaccineimmunityofmrna1273amongpeoplelivingwithhivineastandsouthernafricaaprospectivecohortanalysisfromthemulticentrecovpn3008ubuntustudyresearchincontext AT aliciatoledano hybridversusvaccineimmunityofmrna1273amongpeoplelivingwithhivineastandsouthernafricaaprospectivecohortanalysisfromthemulticentrecovpn3008ubuntustudyresearchincontext AT stephanievanwyk hybridversusvaccineimmunityofmrna1273amongpeoplelivingwithhivineastandsouthernafricaaprospectivecohortanalysisfromthemulticentrecovpn3008ubuntustudyresearchincontext AT shamayawhitby hybridversusvaccineimmunityofmrna1273amongpeoplelivingwithhivineastandsouthernafricaaprospectivecohortanalysisfromthemulticentrecovpn3008ubuntustudyresearchincontext AT stephanywilcox hybridversusvaccineimmunityofmrna1273amongpeoplelivingwithhivineastandsouthernafricaaprospectivecohortanalysisfromthemulticentrecovpn3008ubuntustudyresearchincontext AT eduanwilkinson hybridversusvaccineimmunityofmrna1273amongpeoplelivingwithhivineastandsouthernafricaaprospectivecohortanalysisfromthemulticentrecovpn3008ubuntustudyresearchincontext AT havenwilvich hybridversusvaccineimmunityofmrna1273amongpeoplelivingwithhivineastandsouthernafricaaprospectivecohortanalysisfromthemulticentrecovpn3008ubuntustudyresearchincontext AT charleswiysonge hybridversusvaccineimmunityofmrna1273amongpeoplelivingwithhivineastandsouthernafricaaprospectivecohortanalysisfromthemulticentrecovpn3008ubuntustudyresearchincontext AT nelisiwexaba hybridversusvaccineimmunityofmrna1273amongpeoplelivingwithhivineastandsouthernafricaaprospectivecohortanalysisfromthemulticentrecovpn3008ubuntustudyresearchincontext AT ntokozoxulu hybridversusvaccineimmunityofmrna1273amongpeoplelivingwithhivineastandsouthernafricaaprospectivecohortanalysisfromthemulticentrecovpn3008ubuntustudyresearchincontext |